Immunotherapy

Healio spoke with Charu Aggarwal, MD, MPH, about results from the Keynote-671 trial presented at this year’s ASCO Annual Meeting.

Women receiving cancer treatment in clinical trials exhibited higher risk for severe symptomatic and hematologic adverse events than their male counterparts, according to a study.

Subcutaneous immunotherapy for house dust mite allergy may slightly protect patients against SARS-CoV-2 infection, especially after the dose-escalation phase, according to a letter published in Clinical and Translational Allergy.

Healio spoke with Karen L. Reckamp, MD, about research on perioperative lung cancer presented at ASCO Annual Meeting.

A series of studies showed that loss of the Y chromosome helps cancer evade the body’s immune system response, resulting in more aggressive bladder cancer in men as they age.

CHICAGO — Tumor lymph node dissection likely can be omitted for patients with melanoma who achieve major pathologic response after neoadjuvant immune checkpoint blockade, according to study results presented at ASCO Annual Meeting.

CHICAGO — The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes for patients with early-stage resectable non-small cell lung cancer, according to findings presented at ASCO Annual Meeting.

Healio compiled the most-read news in allergy, asthma and immunology posted in May.

The combination of intratumoral DNX-2401 and pembrolizumab appeared safe and provided “notable survival benefits” for select patients with recurrent glioblastoma, according to a study published in Nature Medicine.

In this edition, we bring you a deep dive on a collaboration that aims to accelerate better treatments for pediatric cancers.